Relief Therapeutics Holding AG (RLFTF)

[djhfsu]

The primary endpoint was 28 day survival. Aviptadil saw a 3 fold benefit (P<.001)

19 of 21 aviptadil-treated patients survived
8 of 30 Maximum Standard of care (MSOC) control patients survived
90% vs. 27%; P<.001

12 Aviptadil treated patients vs. 3 MSOC control patients have returned home or to non-acute care settings (57% vs. 13%; p<001)

An additional 5 Aviptadil patients who remain in the hospital have good potential to recover (ordinal scale 7 or better)

The currently surviving MSOC control patients who remain in the hospital are all on ECHMO and not improving.